Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.7K
Overview
51.7K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.1K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.1K
Language Development01:22

Language Development

918
Children master language quickly and with relative ease, supported by both biological predisposition and reinforcement. B. F. Skinner (1957) proposed that language is learned through reinforcement, while Noam Chomsky (1965) argued that language acquisition mechanisms are biologically determined.
The critical period for language acquisition suggests that the ability to acquire language is at its peak early in life. As people age, this proficiency decreases. Language development begins very...
918
Development of Immunocompetence01:22

Development of Immunocompetence

906
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
906

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days.

bioRxiv : the preprint server for biology·2026
Same author

Comparison of Ebola virus infection routes and resulting disease in animal models.

Journal of virology·2026
Same author

Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.

Journal of virology·2026
Same author

Transcriptional signatures of rapid protection from Sudan virus infection by a single dose of a vesicular stomatitis virus-based vaccine.

PLoS pathogens·2026
Same author

Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection.

Vaccine·2026
Same author

Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge.

bioRxiv : the preprint server for biology·2026
Same journal

Circadian Control of Host-Microbiome Symbioses.

Annual review of microbiology·2026
Same journal

Host-Pathogen Interactions in Malaria: Invasion, Neutralization, and Evasion.

Annual review of microbiology·2026
Same journal

From an Interest in Molecules to a Fascination with Microbes.

Annual review of microbiology·2026
Same journal

Bacterial Physiology in the Context of Algal Partners.

Annual review of microbiology·2026
Same journal

Introduction.

Annual review of microbiology·2025
Same journal

Decoding Microbial Community Assembly: Insights on Vectors of Infectious Diseases.

Annual review of microbiology·2025
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K

Ebola: Lessons on Vaccine Development.

Heinz Feldmann1,2, Friederike Feldmann3, Andrea Marzi1

  • 1Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana 59840, USA;

Annual Review of Microbiology
|September 12, 2018
PubMed
Summary
This summary is machine-generated.

The West African Ebola virus (EBOV) epidemic accelerated vaccine development, providing crucial data on safety and efficacy. Lessons learned from these trials are vital for future preparedness against emerging zoonotic diseases.

Keywords:
Ebola virusanimal modelschallengesclinical trialslessons learnedvaccines

More Related Videos

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.0K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.3K

Related Experiment Videos

Last Updated: Feb 5, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.0K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.3K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Epidemiology

Background:

  • The 2013-2014 West African Ebola virus (EBOV) epidemic highlighted the urgent need for effective countermeasures against emerging zoonotic pathogens.
  • Historically, EBOV vaccine development faced significant hurdles including funding issues and limited pharmaceutical interest, stalling progress between preclinical and clinical stages.

Purpose of the Study:

  • To review the progress and outcomes of Ebola virus vaccine candidates during the West African epidemic.
  • To identify lessons learned from clinical trials conducted during the epidemic to improve future preparedness and response strategies.

Main Methods:

  • Review of vaccine candidates that advanced to clinical trials during the EBOV epidemic.
  • Analysis of data on vaccine safety, immunogenicity, and efficacy from human trials.

Main Results:

  • Ebola virus vaccine candidates progressed to clinical trials late in the epidemic, providing valuable safety and immunogenicity data.
  • While not impacting the ongoing epidemic significantly, the trials yielded critical insights into human responses to vaccination.

Conclusions:

  • Clinical trials during the EBOV epidemic provided essential data for future vaccine development and preparedness.
  • Sustained interest and investment are crucial for maintaining readiness to combat future outbreaks of EBOV and similar emerging infectious diseases.